4-benzyloxy-9-(2-methoxy-ethyl)-9H-carbazole 在
钯乙酸乙酯 作用下,
以
2-四氢呋喃-2-乙醇 为溶剂,
反应 18.0h,
以to afford 9-(2-methoxy-ethyl)-9H-carbazol-4-ol (79) as a brown gum (394 mg, 75% yield, 83% pure by LC-MS and 1H-nmr)的产率得到9-(2-methoxy-ethyl)-9H-carbazol-4-ol
参考文献:
名称:
Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase
[EN] CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE<br/>[FR] COMPOSES CARDIOTONIQUES DOTES D'UNE ACTIVITE INHIBITRICE DIRIGEE CONTRE LES RECEPTEURS BETA-ADRENERGIQUES ET LA PHOSPHODIESTERASE
申请人:ARTESIAN THERAPEUTICS INC
公开号:WO2006060122A3
公开(公告)日:2007-03-22
CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE
申请人:Artesian Therapeutics, Inc.
公开号:EP1833480A2
公开(公告)日:2007-09-19
Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase
申请人:Taylor Malcolm George
公开号:US20080255134A1
公开(公告)日:2008-10-16
The present invention provides compounds of formula (I) possessing inhibitory activity against β adrenergic receptors and phosphodiesterase (PDE), including type 3 phosphodiesterase (PDE-3). The present invention further provides pharmaceutical compositions comprising such compounds, methods of preparing such compounds, and methods of using such compounds for regulating calcium homeostasis, for treating a disease, disorder or condition in which disregulation of calcium homeostasis is implicated and for treating cardiovascular disease, stroke, epilepsy, an ophthalmic disorder or migraine.